EATON
5.7.2022 11:02:09 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced its involvement in a pan-European research and innovation project to deliver the integrated technologies and business models needed to support mass deployment of electric vehicle charging infrastructure.
Supported by the European Union’s Horizon Europe Research and Innovation program, the €9.87M ($10.41M) project will span four years to March 2026, its scope covering the entire electric vehicle charging value chain. The FLOW project consortium, which includes 24 external partners and six leading universities across Europe, will be led by the Fundació Institut De Recerca En Energia De Catalunya .
Eaton’s role in the consortium will involve further developing electric vehicle charging technologies, as well as demonstrating electric vehicle charging solutions, based on experience advancing its Buildings as a Grid approach to uniting the power needs of buildings and electric vehicles with on-site renewable energy generation.
The research and innovation focus will extend across vehicle-to-grid (V2G) and vehicle-to-everything (V2X) capabilities that enable more system flexibility; DC-DC charging (direct current to direct current) that yields both power quality and control benefits; and further work on Eaton’s proprietary Buildings as a Grid Energy Management System that supports forecasting, optimization, and other essential services. To combine the various technologies into a complete solution, several Eaton business units will collaborate on the project—including the pan-European Eaton Research Labs team and the Eaton Center for Intelligent Power in Dublin, Ireland.
Stefan Costea, regional technology manager, Eaton Research Labs, said: “As electric vehicles grow in popularity across Europe, a comprehensive range of fully integrated charging technologies is urgently needed to support mass deployment and enable valuable new services. As a key partner in the FLOW project, we’re thrilled to be developing optimal solutions for electric vehicle charging, V2G, V2X, and energy management. We will demonstrate these technologies at three test labs—at the Eaton European Innovation Center in Prague, at University College Dublin , and at the Fundació Institut De Recerca En Energia De Catalunya, in Barcelona. Additionally, we will be supporting large scale technology demonstrations in Rome and Copenhagen with our energy management systems.”
For the demonstrations in Prague and Barcelona, Eaton will be collaborating closely with Heliox , a market leader in fast charging solutions. University College Dublin and nearby Maynooth University will work with Eaton in Ireland, while RWTH Aachen University , in Germany, will partner with Eaton in Prague on a techno-economic analysis of electric vehicle charging infrastructure use cases. In Rome and Copenhagen, Eaton will collaborate on energy management system interoperability with companies well-known for transmission and distribution: ENEL , Terna , and Areti, in addition to partners at Ricerca Sul Sistema Energetico and the Technical University of Denmark .
Tim Darkes, President, Corporate and Electrical, EMEA, Eaton, explained the context for Eaton’s involvement in the FLOW consortium, saying: “Our work on integrating charging infrastructure into buildings is supporting the rapid move to electric vehicles as part of the energy transition and we’re very proud to be investing heavily in the people, technologies, and programs to accelerate the global drive towards a low-carbon future.”
Jörgen von Bodenhausen, senior manager, Government Programs, Eaton, also added: “We continually seek out opportunities to combine our global scale and expertise with that of world-class industrial and academic partners, thus magnifying our own innovation efforts. From building-in energy management, to DC-DC charging, our work on the FLOW project will help pioneer new solutions to accelerate the commercialization and mass deployment of electric vehicle charging infrastructure and create whole new value propositions for both companies and customers.”
About Eaton
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com . Follow us on Twitter and LinkedIn .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005048/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom